This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido


A.  Vandetanib is considered medically indicated in the treatment of metastatic or unresectable locally advanced medullary thyroid cancer (symptomatic or progressive)..
B.    The decision to treat a patient with vandetanib must be based on the following criteria:

a.    Base Electrocardiogram

b.    Base electrolyte as: K, Ca and Mg

c.     Base TSH

C.    By Triple-S, it is considered for payment for the treatment with vendetanib in the following conditions, identified by their corresponding ICD-10 codes.

D.    Triple-S does not consider for payment the use of vandetanib under the following circumstances:

a.    When there is documentation of:

i.    Congenital syndrome with prolongation of the QT segment

ii.    <18 years of age Off label indication;  Non-Small Cell Lung Cancer ; Patient’s tumor is confirmed to have RET gene rearrangements

787-277-6653 787-474-6326